The assessment of antimalarial drug efficacy.

[1]  M. Bangs,et al.  Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia , 2002, The Lancet.

[2]  L. Aarons,et al.  Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection , 2002, Parasitology.

[3]  R. Snow,et al.  The past, present and future of childhood malaria mortality in Africa. , 2001, Trends in parasitology.

[4]  P. Newton,et al.  Contribution of humoral immunity to the therapeutic response in falciparum malaria. , 2001, The American journal of tropical medicine and hygiene.

[5]  J. M. Rubio,et al.  Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[6]  Leon Aarons,et al.  Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance , 2000, Antimicrobial Agents and Chemotherapy.

[7]  C. Newbold,et al.  The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. , 2000, The Journal of infectious diseases.

[8]  J. Simpson,et al.  Therapeutic Responses to Different Antimalarial Drugs in Vivax Malaria , 2000, Antimicrobial Agents and Chemotherapy.

[9]  S. Heisterkamp,et al.  Combinations of Artemisinin and Quinine for Uncomplicated Falciparum Malaria: Efficacy and Pharmacodynamics , 2000, Antimicrobial Agents and Chemotherapy.

[10]  N. White,et al.  Editorial: Antimalarial drug resistance and mortality in falciparum malaria , 1999, Tropical medicine & international health : TM & IH.

[11]  N. White.  Antimalarial drug resistance and mortality in falciparum malaria [editorial] , 1999 .

[12]  R. Snow,et al.  Averting a malaria disaster , 1999, The Lancet.

[13]  N. White,et al.  Antimalarial drug resistance and combination chemotherapy. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[14]  Baird Jk.  Primaquine as anti-relapse therapy for Plasmodium vivax. , 1998 .

[15]  J. Baird,et al.  Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia. , 1998, The American journal of tropical medicine and hygiene.

[16]  K. Marsh.  Malaria disaster in Africa , 1998, The Lancet.

[17]  N. White,et al.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.

[18]  Suradi,et al.  Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. , 1997, The American journal of tropical medicine and hygiene.

[19]  N. White,et al.  Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. , 1996, Blood.

[20]  J. Baird,et al.  Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[21]  S. Pukrittayakamee,et al.  Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. , 1994, The Journal of infectious diseases.

[22]  F. Smithuis,et al.  Comparison of two mefloquine regimens for treatment of Plasmodium falciparum malaria on the northeastern Thai-Cambodian border , 1993, Antimicrobial Agents and Chemotherapy.

[23]  F. T. Ter Kuile,et al.  Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. , 1993, Experimental parasitology.

[24]  D. Kwiatkowski,et al.  OPEN COMPARISON OF INTRAMUSCULAR CHLOROQUINE AND QUININE IN CHILDREN WITH SEVERE CHLOROQUINE-SENSITIVE FALCIPARUM MALARIA , 1989, The Lancet.

[25]  N. White,et al.  Treatment of malaria: some considerations and limitations of the current methods of assessment. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[26]  P. Garnham.  Malaria Parasites and Other Haemosporidia , 1966 .

[27]  W. Yorke,et al.  Observations on malaria made during treatment of general paralysis , 1924 .

[28]  J. Trape.  The public health impact of chloroquine resistance in Africa. , 2001, The American journal of tropical medicine and hygiene.

[29]  P. Bloland,et al.  Monitoring antimalarial drug resistance (report of a WHO Consultation) , 2001 .

[30]  F. Nosten,et al.  Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. , 1999, The American journal of tropical medicine and hygiene.

[31]  J. Baird.  Primaquine as anti-relapse therapy for Plasmodium vivax. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[32]  W. Jarra,et al.  Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. , 1995, Bulletin of the World Health Organization.

[33]  W. Wernsdorfer,et al.  Chemotherapy of malaria , 1981 .

[34]  Resistance to Antimalarials.  Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group. , 1973, World Health Organization technical report series.

[35]  D. G. Davey.  Chemotherapy of malaria. , 1951, British medical bulletin.